Neurotensin is increased in serum of young children with autistic disorder

Journal of Neuroinflammation

Volumn 7, Issue , 2010, Pages

  Angelidou, Asimenia ^a,b   Francis, Konstantinos ^b   Vasiadi, Magdalini ^a,b   Alysandratos, Konstantinos Dionysios ^a,b   Zhang, Bodi ^a   Theoharides, Athanasios ^c   Lykouras, Lefteris ^b   Sideri, Kyriaki ^b   Kalogeromitros, Dimitrios ^b   Theoharides, Theoharis C ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c Institute of Social Health Insurance (IKA)   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ENDORPHIN; NEUROTENSIN; SUBSTANCE P;

ARTICLE; AUTISM; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INFLAMMATION; MALE; MAST CELL; PRESCHOOL CHILD; PROTEIN BLOOD LEVEL; BLOOD; NONPARAMETRIC TEST;

AUTISTIC DISORDER; BETA-ENDORPHIN; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; NEUROTENSIN; STATISTICS, NONPARAMETRIC; SUBSTANCE P;

EID: 77955834453     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-7-48     Document Type: Article

References (42)

1. Volkmar FR, State M, Klin A. Autism and autism spectrum disorders: diagnostic issues for the coming decade. J Child Psychol Psychiatry 2009, 50:108-115. 10.1111/j.1469-7610.2008.02010.x, 19220594.
2. Johnson CP, Myers SM. Identification and evaluation of children with autism spectrum disorders. Pediatrics 2007, 120:1183-1215. 10.1542/peds.2007-2361, 17967920.
3. Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr Res 2009, 65:591-598. 10.1203/PDR.0b013e31819e7203, 19218885.
4. Kogan MD, Blumberg SJ, Schieve LA, Boyle CA, Perrin JM, Ghandour RM, et al. Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007. Pediatrics 2009, 5:1395-1403.
5. Theoharides TC, Doyle R, Francis K, Conti P, Kalogeromitros D. Novel therapeutic targets for autism. Trends Pharmacol Sci 2008, 29:375-382. 10.1016/j.tips.2008.06.002, 18606459.
6. Ashwood P, Wills S, Van de Water J. The immune response in autism: a new frontier for autism research. J Leukoc Biol 2006, 80:1-15. 10.1189/jlb.1205707, 16698940.
7. Atladottir HO, Pedersen MG, Thorsen P, Mortensen PB, Deleuran B, Eaton WW, et al. Association of family history of autoimmune diseases and autism spectrum disorders. Pediatrics 2009, 124:687-694. 10.1542/peds.2008-2445, 19581261.
8. Theoharides TC, Kempuraj D, Redwood L. Autism: an emerging 'neuroimmune disorder' in search of therapy. Exp Opinion on Pharmacotherapy 2009, 10:2127-2143.
9. Heinrichs M, von DB, Domes G. Oxytocin, vasopressin, and human social behavior. Front Neuroendocrinol 2009, 30:548-557. 10.1016/j.yfrne.2009.05.005, 19505497.
10. Nelson KB, Grether JK, Croen LA, Dambrosia JM, Dickens BF, Jelliffe LL, et al. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann Neurol 2001, 49:597-606. 10.1002/ana.1024, 11357950.
11. Nelson PG, Kuddo T, Song EY, Dambrosia JM, Kohler S, Satyanarayana G, et al. Selected neurotrophins, neuropeptides, and cytokines: developmental trajectory and concentrations in neonatal blood of children with autism or Down syndrome. Int J Dev Neurosci 2006, 24:73-80. 10.1016/j.ijdevneu.2005.10.003, 16289943.
12. Ross DL, Klykylo WM, Hitzemann R. Reduction of elevated CSF beta-endorphin by fenfluramine in infantile autism. Pediatr Neurol 1987, 3:83-86. 10.1016/0887-8994(87)90032-4, 2977280.
13. Theoharides TC, Kalogeromitros D. The critical role of mast cell in allergy and inflammation. Ann NY Acad Sci 2006, 1088:78-99. 10.1196/annals.1366.025, 17192558.
14. Papanikolaou K, Paliokosta E, Houliaras G, Vgenopoulou S, Giouroukou E, Pehlivanidis A, et al. Using the Autism Diagnostic Interview-Revised and the Autism Diagnostic Observation Schedule-Generic for the Diagnosis of Autism Spectrum Disorders in a Greek Sample with a Wide Range of Intellectual Abilities. J Autism Dev Disord 2008, 39:414-420. 10.1007/s10803-008-0639-6, 18752062.
15. Liu J, Zhao J, Di YF, Guo XX, Zhai GR, Huang XH. The dynamic changes of plasma neuropeptide y and neurotensin and their role in regulating cerebral hemodynamics in neonatal hypoxic-ischemic encephalopathy. Am J Perinatol 2007, 24:435-440. 10.1055/s-2007-985047, 17616921.
16. Bozzola M, Ntodou-Thome A, Bona G, Autelli M, Magnani ML, Radetti G, et al. Possible role of plasma neurotensin on growth hormone regulation in neonates. J Pediatr Endocrinol Metab 1998, 11:607-613.
17. Carraway R, Leeman SE. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem 1973, 248:6854-6861.
18. Castagliuolo I, Leeman SE, Bartolac-Suki E, Nikulasson S, Qiu B, Carraway RE, et al. A neurotensin antagonist, SR 48692, inhibits colonic responses to immobilization stress in rats. Proc Natl Acad Sci USA 1996, 93:12611-12615. 10.1073/pnas.93.22.12611, 38040, 8901630.
19. Evers BM, Bold RJ, Ehrenfried JA, Li J, Townsend CM, Klimpel GR. Characterization of functional neurotensin receptors on human lymphocytes. Surgery 1994, 116:134-139.
20. Ramez M, Bagot M, Nikolova M, Boumsell L, Vita N, Chalon P, et al. Functional characterization of neurotensin receptors in human cutaneous T cell lymphoma malignant lymphocytes. J Invest Dermatol 2001, 117:687-693. 10.1046/j.0022-202x.2001.01439.x, 11564178.
21. Lemaire I. Neurotensin enhances IL-1 production by activated alveolar macrophages. J Immunol 1988, 140:2983-2988.
22. Carraway R, Cochrane DE, Lansman JB, Leeman SE, Paterson BM, Welch HJ. Neurotensin stimulates exocytotic histamine secretion from rat mast cells and elevates plasma histamine levels. J Physiol 1982, 323:403-414. 1250364, 6178820.
23. Gurney JG, McPheeters ML, Davis MM. Parental report of health conditions and health care use among children with and without autism: National Survey of Children's Health. Arch Pediatr Adolesc Med 2006, 160:825-830. 10.1001/archpedi.160.8.825, 16894082.
24. Jyonouchi H, Geng L, Cushing-Ruby A, Quraishi H. Impact of innate immunity in a subset of children with autism spectrum disorders: a case control study. J Neuroinflammation 2008, 5:52. 10.1186/1742-2094-5-52, 2625336, 19025588.
25. Magalhaes ES, Pinto-Mariz F, Bastos-Pinto S, Pontes AT, Prado EA, Deazevedo LC. Immune allergic response in Asperger syndrome. J Neuroimmunol 2009, 216:108-112. 10.1016/j.jneuroim.2009.09.015, 19840888.
26. Bakkaloglu B, Anlar B, Anlar FY, Oktem F, Pehlivanturk B, Unal F, et al. Atopic features in early childhood autism. Eur J Paediatr Neurol 2008, 12:476-479. 10.1016/j.ejpn.2007.12.008, 18272414.
27. Theoharides TC. Autism spectrum disorders and mastocytosis. Int J Immunopathol Pharmacol 2009, 22:859-865.
28. Akin C, Valent P, Escribano L. Urticaria pigmentosa and mastocytosis: the role of immunophenotyping in diagnosis and determining response to treatment. Curr Allergy Asthma Rep 2006, 6:282-288. 10.1007/s11882-006-0061-0, 16822380.
29. Castells M. Mast cell mediators in allergic inflammation and mastocytosis. Immunol Allergy Clin North Am 2006, 26:465-485. 10.1016/j.iac.2006.05.005, 16931289.
30. Kempuraj D, Asadi S, Zhang B, Manola A, Hogan J, Peterson E, et al. Mercury induces inflammatory mediator release from human mast cells. J Neuroinflammation 2010, 7. 10.1186/1742-2094-7-20, 2850891, 20222982.
31. Donelan J, Boucher W, Papadopoulou N, Lytinas M, Papaliodis D, Theoharides TC. Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. Proc Natl Acad Sci USA 2006, 103:7759-7764. 10.1073/pnas.0602210103, 1472518, 16682628.
32. Beversdorf DQ, Manning SE, Hillier A, Anderson SL, Nordgren RE, Walters SE, et al. Timing of prenatal stressors and autism. J Autism Dev Disord 2005, 35:471-478. 10.1007/s10803-005-5037-8, 16134032.
33. Cochrane DE, Carraway RE, Boucher W, Feldberg RS. Rapid degradation of neutotensin by stimulated rat mast cells. Peptides 1991, 12:1187-1194. 10.1016/0196-9781(91)90193-S, 1726119.
34. Piliponsky AM, Chen CC, Nishimura T, Metz M, Rios EJ, Dobner PR, et al. Neurotensin increases mortality and mast cells reduce neurotensin levels in a mouse model of sepsis. Nat Med 2008, 14:392-398. 10.1038/nm1738, 2873870, 18376408.
35. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol 2005, 23:749-786. 10.1146/annurev.immunol.21.120601.141025, 15771585.
36. Theoharides TC, Kempuraj D, Tagen M, Conti P, Kalogeromitros D. Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev 2007, 217:65-78. 10.1111/j.1600-065X.2007.00519.x, 17498052.
37. Li X, Chauhan A, Sheikh AM, Patil S, Chauhan V, Li XM, et al. Elevated immune response in the brain of autistic patients. J Neuroimmunol 2009, 207:111-116. 10.1016/j.jneuroim.2008.12.002, 2770268, 19157572.
38. Zimmerman AW, Jyonouchi H, Comi AM, Connors SL, Milstien S, Varsou A, et al. Cerebrospinal fluid and serum markers of inflammation in autism. Pediatr Neurol 2005, 33:195-201. 10.1016/j.pediatrneurol.2005.03.014, 16139734.
39. Croonenberghs J, Bosmans E, Deboutte D, Kenis G, Maes M. Activation of the inflammatory response system in autism. Neuropsychobiology 2002, 45:1-6. 10.1159/000048665, 11803234.
40. Chez MG, Dowling T, Patel PB, Khanna P, Kominsky M. Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. Pediatr Neurol 2007, 36:361-365. 10.1016/j.pediatrneurol.2007.01.012, 17560496.
41. Gibbs BF, Wierecky J, Welker P, Henz BM, Wolff HH, Grabbe J. Human skin mast cells rapidly release preformed and newly generated TNF-alpha and IL-8 following stimulation with anti-IgE and other secretagogues. Exp Dermatol 2001, 10:312-320. 10.1034/j.1600-0625.2001.100503.x, 11589728.
42. Cocchiara R, Albeggiani G, Lampiasi N, Bongiovanni A, Azzolina A, Geraci D. Histamine and tumor necrosis factor-a production from purified rat brain mast cells mediated by substance P. Neuroreport 1999, 10:575-578. 10.1097/00001756-199902250-00024, 10208592.